Rhythm Pharmaceuticals (RYTM) Net Income towards Common Stockholders (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Net Income towards Common Stockholders of -$56.7 million for Q1 2026, down 11.65% year-over-year from -$64.2 million in Q1 2025, and down 16.19% quarter-over-quarter from -$48.8 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Net Income towards Common Stockholders for 11 consecutive years, with -$56.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 11.65% year-over-year to -$56.7 million; the TTM figure through Mar 2026 stood at -$207.8 million (down 19.46% YoY), while the FY2025 annual figure was -$201.9 million, up 23.68% from the prior year.
- Net Income towards Common Stockholders eased to -$56.7 million in Q1 2026 per RYTM's latest filing, from -$48.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$33.6 million in Q2 2024 and bottomed at -$141.4 million in Q1 2024.
- Historically, Net Income towards Common Stockholders has averaged -$52.6 million across 5 years, with a median of -$47.4 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 226.48% — and 2025, when it jumped 64.05%.
- Rhythm Pharmaceuticals' Net Income towards Common Stockholders stood at -$42.5 million in 2022, then rose by 2.02% to -$41.6 million in 2023, then dropped by 7.2% to -$44.6 million in 2024, then decreased by 9.42% to -$48.8 million in 2025, then declined by 16.19% to -$56.7 million in 2026.
- Business Quant data shows RYTM's Net Income towards Common Stockholders at -$56.7 million in Q1 2026, -$48.8 million in Q4 2025, and -$54.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | -50.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.36 Mn |
| Mar 31, 2026 | -56.74 Mn |
| Dec 31, 2025 | -48.84 Mn |
| Sep 30, 2025 | -54.28 Mn |
| Jun 30, 2025 | -47.98 Mn |
| Mar 31, 2025 | -50.82 Mn |
| Dec 31, 2024 | -44.63 Mn |
| Sep 30, 2024 | -44.97 Mn |
| Jun 30, 2024 | -33.56 Mn |
| Mar 31, 2024 | -141.37 Mn |
| Dec 31, 2023 | -41.63 Mn |
| Sep 30, 2023 | -44.16 Mn |
| Jun 30, 2023 | -46.70 Mn |
| Mar 31, 2023 | -52.18 Mn |
| Dec 31, 2022 | -42.49 Mn |
| Sep 30, 2022 | -40.86 Mn |
| Jun 30, 2022 | -47.42 Mn |
| Mar 31, 2022 | -55.33 Mn |
| Dec 31, 2021 | -54.07 Mn |
| Sep 30, 2021 | -38.32 Mn |